Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

FDA Approves fam-Trastuzumab Deruxtecan-nxki for HER2-Low Breast Cancer

Evidence for efficacy is based on the results from the DESTINY-Breast04 study
24 Aug 2022
Anticancer agents & Biologic therapy;  Breast cancer;  Personalised medicine

On 5 August 2022, the US Food and Drug Administration approved fam-trastuzumab deruxtecan-nxki (Enhertu, Daiichi Sankyo, Inc.) for adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH‑) breast cancer who have received a prior chemotherapy in the metastatic setting or developed disease recurrence during or within 6 months of completing adjuvant chemotherapy.

Efficacy was based on DESTINY-Breast04 (NCT03734029), a randomised, multicentre, open-label clinical study that enroled 557 patients with unresectable or metastatic HER2-low breast cancer. The study included two cohorts: 494 patients with hormone receptor (HR)-positive and 63 with HR-negative breast cancer. HER2-low expression was defined as IHC 1+ or IHC 2+/ISH-, determined at a central laboratory. Patients were randomised (2:1) to receive either Enhertu 5.4 mg/kg (N=373) by intravenous infusion every 3 weeks or physician’s chemotherapy choice (N=184, including eribulin, capecitabine, gemcitabine, nab-paclitaxel, or paclitaxel).

The primary efficacy measure was progression-free survival (PFS) in patients with HR-positive breast cancer, assessed by blinded independent central review using RECIST v1.1. Secondary efficacy measures were PFS in the overall population (all randomised HR-positive and HR-negative patients), overall survival (OS) in HR-positive patients, and OS in the overall population.

The median age of patients was 57 years (range: 28 to 81) and 24% were 65 or older. Selected demographics were reported as follows: 99.6% female, 48% White, 40% Asian, 2% Black or African American, 3.8% Hispanic/Latino.

Median PFS in the HR-positive cohort was 10.1 months (95% confidence interval [CI] 9.5, 11.5) in the Enhertu arm and 5.4 months (95% CI 4.4, 7.1) in the chemotherapy arm (hazard ratio [HR] 0.51, 95% CI: 0.40, 0.64; p < 0.0001). Median PFS in the overall population was 9.9 months (95% CI 9.0, 11.3) in the Enhertu arm and 5.1 months (95% CI 4.2, 6.8) for those receiving chemotherapy (HR 0.50, 95% CI: 0.40, 0.63; p < 0.0001).

In the HR-positive cohort, median OS was 23.9 months (95% CI 20.8, 24.8) and 17.5 months (95% CI 15.2, 22.4) in the Enhertu and chemotherapy arms, respectively (HR 0.64, 95% CI 0.48, 0.86; p = 0.0028). In the overall population, median OS was 23.4 months (95% CI 20.0, 24.8) in the Enhertu arm versus 16.8 months (95% CI 14.5, 20.0) in the chemotherapy arm (HR 0.64, 95% CI 0.49, 0.84; p = 0.001).

The most common adverse reactions (incidence ≥20%) in patients receiving Enhertu in this study were nausea, fatigue, alopecia, vomiting, anaemia, constipation, decreased appetite, diarrhoea, and musculoskeletal pain. The prescribing information includes a Boxed Warning advising health professionals of the risk of interstitial lung disease and embryo-foetal toxicity.

The recommended Enhertu dose for breast cancer is 5.4 mg/kg given as an intravenous infusion once every 3 weeks (21-day cycle) until disease progression or unacceptable toxicity.

Full prescribing information for Enhertu is available here.

This review was conducted under Project Orbis, an initiative of the FDA Oncology Center of Excellence (OCE). Project Orbis provides a framework for concurrent submission and review of oncology drugs among international partners. For this review, FDA collaborated with the Australian Therapeutic Goods Administration, Health Canada, and Switzerland’s Swissmedic. The application reviews may be ongoing at the other regulatory agencies.

This review used the Real-Time Oncology Review programme, which streamlined data submission prior to the filing of the complete clinical application, and the Assessment Aid, a voluntary submission from the applicant to facilitate the FDA’s assessment. The FDA approved this application approximately 4 months ahead of the FDA goal date.

This application was granted priority review and breakthrough therapy designation.

Healthcare professionals should report all serious adverse events suspected to be associated with the use of any medicine and device to FDA’s MedWatch Reporting System.

For assistance with single-patient INDs for investigational oncology products, healthcare professionals may contact OCE’s Project Facilitate.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.